A unit of Chinese contract drugmaker Wuxi Biologics has experienced overwhelming demand for its initial public offering (IPO) in Hong Kong, closing its order book early and potentially pricing the deal at the top of its marketed range, according to sources familiar with the matter. This is a remarkable occurrence in a year that has seen a turbulent market for listings in Hong … [Read more...] about Wuxi XDC Cayman: Strong Demand for IPO in Hong Kong
cancer treatment
Clinical Collaboration Agreement for Deflexifol
Allarity Therapeutics and Detsamma Investments, trading as FivepHusion, have recently announced a significant clinical collaboration agreement for the development of Deflexifol. Advancing Treatment for Solid Tumors The collaboration aims to propel the clinical development of Deflexifol, a novel anti-cancer drug reformulation, for the treatment of solid tumors. Allarity will … [Read more...] about Clinical Collaboration Agreement for Deflexifol
